Kazuhiko Iikubo

This inventor holds 7 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignees: Astellas Pharma Gmbh, Kotobuki Pharmaceutical Co Ltd. Active years: 2009-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kazuhiko Iikubo. Retrieved from https://idiyas.com/inventor/kazuhiko-iikubo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 2)

% Patents Active = 42.9

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 9.7

ph-index = 4

Forward Citations = 70(Granted Patents)

Location History:

Tokyo, JP (2009 - 2016)
Chuo-ku, JP (2014 - 2016)

Company Filing History:

Kotobuki Pharmaceutical Co Ltd

patents

where one patent can have more than one assignee

Years Active: 2009-2016

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9487491 - Diamino heterocyclic carboxamide compound (2016-11-08),

2. 9464077 - Nitrogen-containing aromatic heterocyclic compound (2016-10-11),

3. 8969336 - Diamino heterocyclic carboxamide compound (2015-03-03),

4. 8822688 - Imidazo[1,2-a]pyridine derivative (2014-09-02),

5. 8318702 - Di(arylamino)aryl compounds (2012-11-27),

6. 7947690 - Pyrimidine derivative condensed with a non-aromatic ring (2011-05-24),

7. 7557112 - Aromatic-ring-fused pyrimidine derivative (2009-07-07),

Title: Biography of Kazuhiko Iikubo

Introduction: Kazuhiko Iikubo is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for cancer treatment. With a total of seven patents to his name, Iikubo's work has had a substantial impact on medical research and therapeutic applications.

Latest Patents: One of his latest patents includes a diamino heterocyclic carboxamide compound, which serves as an inhibitor against the kinase activity of the EML4-ALK fusion protein. This compound has shown potential in preventing and treating various types of cancer, including lung cancer. Another notable patent is for a nitrogen-containing aromatic heterocyclic compound, which acts as a prophylactic and therapeutic agent for bladder cancer. This compound has demonstrated inhibitory action on FGFR1, FGFR2, and FGFR3, particularly targeting mutant FGFR3.

Career Highlights: Kazuhiko Iikubo has worked with notable companies in the pharmaceutical industry, including Astellas Pharma GmbH and Kotobuki Pharmaceutical Co. Ltd. His experience in these organizations has allowed him to contribute to groundbreaking research and development in cancer therapies.

Collaborations: Throughout his career, Iikubo has collaborated with esteemed colleagues, including Itsuro Shimada and Kazuo Kurosawa. These partnerships have fostered innovation and have been

Profile summary based on public USPTO records.